We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Tucatinib Against Stage IV HER2+ Breast Cancer, Phase III Trial Results Promising

News   Dec 12, 2019 | Original story from University of Colorado Cancer Center

 
Tucatinib Against Stage IV HER2+ Breast Cancer,  Phase III Trial Results Promising
 
 
Advertisement
 

RELATED ARTICLES

Mixing COVID-19 Vaccines Increases Side Effects, Preliminary Data Suggests

News

Leaders of the Com-COV study share preliminary findings that suggest combining different COVID-19 vaccines increases the reactogenicity (side effect profile) associated with vaccination.

READ MORE

Tricking Cancer Cells To Consume Toxic Drugs

News

New research points to a possible strategy to boost tumor intake of cancer drugs, thereby increasing the effectiveness of chemotherapy treatments.

READ MORE

Bioluminescent Tool Makes Animals Glow Like Fireflies

News

An international research team is working to harness the power of bioluminescence in a low-cost, noninvasive portable medical imaging device that could one day be applied to many uses in biomedical research, translational medicine and clinical diagnoses.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE